AbbVie (ABBV) Non-Current Deferred Tax Liability (2016 - 2025)
AbbVie (ABBV) has disclosed Non-Current Deferred Tax Liability for 14 consecutive years, with $2.5 billion as the latest value for Q4 2025.
- Quarterly Non-Current Deferred Tax Liability fell 3.76% to $2.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 billion through Dec 2025, down 3.76% year-over-year, with the annual reading at $2.5 billion for FY2025, 3.76% down from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 was $2.5 billion at AbbVie, roughly flat from $2.5 billion in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $3.8 billion in Q1 2021, with the low at $2.0 billion in Q3 2022.
- Average Non-Current Deferred Tax Liability over 5 years is $2.7 billion, with a median of $2.6 billion recorded in 2024.
- The sharpest move saw Non-Current Deferred Tax Liability soared 292.91% in 2021, then tumbled 45.25% in 2022.
- Over 5 years, Non-Current Deferred Tax Liability stood at $3.0 billion in 2021, then fell by 27.22% to $2.2 billion in 2022, then increased by 21.23% to $2.7 billion in 2023, then fell by 2.86% to $2.6 billion in 2024, then fell by 3.76% to $2.5 billion in 2025.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $2.5 billion, $2.5 billion, and $2.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.